nplex, a Montreal-based startup specializing in innovative protein measurement technologies, has secured pre-seed funding led by 2048 Ventures to enhance diagnostics and drug discovery capabilities.
Information on the Target
nplex is a pioneering company focused on revolutionizing protein measurement technologies. Spun out from McGill University in Montreal, nplex aims to enhance the analysis of proteins in a way that parallels the advancements seen in DNA sequencing. This innovative firm has developed a platform capable of simultaneously analyzing many proteins (n-plex) rather than the traditional single-protein measurements, drastically improving efficiency and scalability.
Founded by David Juncker, a Professor of Biological and Biomedical Engineering, and Dr. Milad Dagher, the CEO of nplex, the company utilizes cutting-edge nanotechnology and sophisticated computational tools. Their platform is designed to seamlessly integrate with existing high-throughput biological workflows, making it highly applicable across various sectors within biology and medicine, including drug discovery, diagnostics, and basic research.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Canada
The biotechnology industry in Canada has experienced significant growth over the past few years. Protein measurement plays a critical role in this sector, as over 40% of clinical tests depend on pro
Similar Deals
Conexus Venture Capital → Alto Technologies Inc.
2025
2048 Ventures
invested in
nplex
in 2023
in a Pre-Seed Stage deal